Trial register facet
Trial records for Thymosin alpha-1
20 records for Thymosin alpha-1, of which 4 are published trials.
Showing 0 records on this page
Records
20 documents
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| TA1-SEPSIS-CN | Thymosin alpha-1 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 361 | 2013 | Moderate |
| TA1-SEPSIS-CN-ADHERENCEprogramme record | Thymosin alpha-1 | Phase 3 | Reported | Observational | — | 2013 | Very low |
| TA1-SEPSIS-CN-BIOMARKERprogramme record | Thymosin alpha-1 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2013 | Very low |
| TA1-SEPSIS-CN-ELDERLYprogramme record | Thymosin alpha-1 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2013 | Very low |
| TA1-SEPSIS-CN-OLEprogramme record | Thymosin alpha-1 | Phase 3 | Reported | Single-arm open-label | — | 2013 | Very low |
| TA1-HCV-1 | Thymosin alpha-1 | Phase 3 | Reported | Randomised, double-blind, active-controlled | — | 2004 | Moderate |
| TA1-HCV-1-REGIONAL-CNprogramme record | Thymosin alpha-1 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2004 | Very low |
| TA1-HCV-1-QOLprogramme record | Thymosin alpha-1 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2004 | Very low |
| TA1-HCV-1-BODY-COMPprogramme record | Thymosin alpha-1 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2004 | Very low |
| TA1-HCV-1-REGIONAL-JPprogramme record | Thymosin alpha-1 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2004 | Very low |
| TA1-HBV-1 | Thymosin alpha-1 | Phase 3 | Reported | Randomised, double-blind, active-controlled | — | 2001 | Moderate |
| TA1-HBV-1-REGIONAL-JPprogramme record | Thymosin alpha-1 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2001 | Very low |
| TA1-HBV-1-BODY-COMPprogramme record | Thymosin alpha-1 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2001 | Very low |
| TA1-HBV-1-QOLprogramme record | Thymosin alpha-1 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2001 | Very low |
| TA1-HBV-1-REGIONAL-CNprogramme record | Thymosin alpha-1 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2001 | Very low |
| TA1-VACCINE-ELDERLY | Thymosin alpha-1 | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 1998 | Moderate |
| TA1-VACCINE-ELDERLY-BODY-COMPprogramme record | Thymosin alpha-1 | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 1998 | Very low |
| TA1-VACCINE-ELDERLY-REGIONAL-JPprogramme record | Thymosin alpha-1 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 1998 | Very low |
| TA1-VACCINE-ELDERLY-REGIONAL-CNprogramme record | Thymosin alpha-1 | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 1998 | Very low |
| TA1-VACCINE-ELDERLY-QOLprogramme record | Thymosin alpha-1 | Phase 2 | Reported | Randomised, double-blind, placebo-controlled | — | 1998 | Very low |